TY - JOUR
T1 - Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia
AU - Pemmaraju, Naveen
AU - Gerds, Aaron T.
AU - Yu, Jingbo
AU - Parasuraman, Shreekant
AU - Shah, Anne
AU - Xi, Ann
AU - Kumar, Shambhavi
AU - Scherber, Robyn M.
AU - Verstovsek, Srdan
N1 - Funding Information:
The authors thank Dilan Paranagama, Ph.D., of Incyte Corporation (Wilmington, DE), for his statistical consultation. Writing assistance was provided by Jane Kovalevich, Ph.D., an employee of ICON (Blue Bell, PA), and was funded by Incyte Corporation. This study was funded by Incyte Corporation .
Publisher Copyright:
© 2022 The Authors
PY - 2022/4
Y1 - 2022/4
N2 - Patients with polycythemia vera (PV) and essential thrombocythemia (ET) have increased thrombotic risk. This retrospective, real-world analysis of Medicare patients (age ≥ 65 years) newly diagnosed with high-risk PV or intermediate-/high-risk ET compared mortality risk among those with versus without thrombotic events during the study period. Patients diagnosed with PV or ET with ≥ 1 inpatient or ≥ 2 outpatient claims (January 1, 2010–December 31, 2017; index was date of first qualifying claim) were included. The study included 50,405 Medicare beneficiaries with PV and 124,569 with ET. During follow-up (median [range]: PV, 34.5 [0–97.3] months; ET, 25.5 [0–97.4] months), 14,334 patients (28.4%) with PV and 30,478 (24.5%) with ET experienced thrombotic events (most commonly ischemic stroke [PV, 46.0%; ET, 42.5%]. Mortality risk was increased for patients with versus without post-index thrombosis for both PV (adjusted hazard ratio [aHR; 95% CI], 18.6 [16.1–21.6]; P < 0.001) and ET (aHR [95% CI], 25.2 [23.1–27.5]; P < 0.001). Median survival was shorter for patients who experienced a thrombotic event ≤ 1 year post-index versus those who did not (PV, 5.1 years vs not reached; ET, 3.7 vs 6.7 years; both P < 0.001). These findings highlight the importance of thrombosis risk mitigation in PV and ET management.
AB - Patients with polycythemia vera (PV) and essential thrombocythemia (ET) have increased thrombotic risk. This retrospective, real-world analysis of Medicare patients (age ≥ 65 years) newly diagnosed with high-risk PV or intermediate-/high-risk ET compared mortality risk among those with versus without thrombotic events during the study period. Patients diagnosed with PV or ET with ≥ 1 inpatient or ≥ 2 outpatient claims (January 1, 2010–December 31, 2017; index was date of first qualifying claim) were included. The study included 50,405 Medicare beneficiaries with PV and 124,569 with ET. During follow-up (median [range]: PV, 34.5 [0–97.3] months; ET, 25.5 [0–97.4] months), 14,334 patients (28.4%) with PV and 30,478 (24.5%) with ET experienced thrombotic events (most commonly ischemic stroke [PV, 46.0%; ET, 42.5%]. Mortality risk was increased for patients with versus without post-index thrombosis for both PV (adjusted hazard ratio [aHR; 95% CI], 18.6 [16.1–21.6]; P < 0.001) and ET (aHR [95% CI], 25.2 [23.1–27.5]; P < 0.001). Median survival was shorter for patients who experienced a thrombotic event ≤ 1 year post-index versus those who did not (PV, 5.1 years vs not reached; ET, 3.7 vs 6.7 years; both P < 0.001). These findings highlight the importance of thrombosis risk mitigation in PV and ET management.
KW - Essential thrombocythemia
KW - Myeloproliferative neoplasms
KW - Polycythemia vera
KW - Survival
KW - Thrombotic events
UR - http://www.scopus.com/inward/record.url?scp=85125143978&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85125143978&partnerID=8YFLogxK
U2 - 10.1016/j.leukres.2022.106809
DO - 10.1016/j.leukres.2022.106809
M3 - Article
C2 - 35220060
AN - SCOPUS:85125143978
SN - 0145-2126
VL - 115
JO - Leukemia Research
JF - Leukemia Research
M1 - 106809
ER -